Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The SPAARK trial has now received OCTRU Green Light approval and can begin recruitment! This is a phase III, multi-centre, patient blinded, randomised controlled trial to evaluate the effectiveness of liposomal bupivacaine with bupivacaine hydrochloride compared to bupivacaine hydrochloride alone on post-operative recovery after knee replacement surgery.